Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040
Authors:
Top Cited Papers
Open Access
- 2 June 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (6) , e2516367
Abstract
Importance: Population-based data for metabolic dysfunction–associated steatotic liver disease (MASLD)–related mortality trends and forecasts in the United States are limited.Objective: To examine MASLD-related mortality trends in the United States from 2006 to 2023 and forecast mortality rates up to 2040 overall and in subgroups by age, sex, race and ethnicity, and urbanization.Design, Setting, and Participants: This cross-sectional study used data from the National Vital Statistics System dataset. Data on deaths attributed to MASLD were obtained for adults aged 25 years and older from January 1, 2006, to December 31, 2023.Main Outcomes and Measures: Trends were evaluated by average annual percentage change (AAPC) in age-standardized mortality rates (ASMRs) per 100 000 persons, and mortality rates were forecasted to 2040 using projection models.Results: A total of 27 961 decedents aged 25 years and older with MASLD (15 251 [54.5%] aged ≥65 years; 15 450 [55.3%] female; 3373 [12.1%] Hispanic, 1480 [5.3%] non-Hispanic Black, and 21 936 [78.5%] non-Hispanic White) were documented from 2006 to 2023. ASMRs rose from 0.25 to 1.27 per 100 000 persons, with AAPCs increasing from 9.27% in 2006 to 2018 to 22.66% in 2018 to 2021, then decreasing to −1.23% from 2021 to 2023, leading to projected ASMRs of 2.24 per 100 000 persons in 2040. There were significant differences in the increases of ASMRs by age, with those aged 65 years or older having the steepest rise (AAPC, 15.34%; 95% CI, 14.40%-16.32%; P < .001; 45-64 years: 8.76%; 95% CI, 7.29%-10.22%; P < .001; 25-44 years: 2.65%; 95% CI, 0.49%-4.86%; P = .02) and a projected increase from 3.69 per 100 000 persons in 2024 to 7.12 per 100 000 persons in 2040. However, there was no significant difference in ASMRs by sex (AAPC among women: 11.24%; 95% CI, 10.09%-12.40%; P < .001; AAPC among men: 11.04%; 95% CI, 9.56%-12.63%; P < .001). ASMRs rose for all major racial ethnic groups, with the highest ASMR increase observed for non-Hispanic White individuals (AAPC, 11.12%; 95% CI, 9.48%-12.83%; P < .001), followed by Hispanic (AAPC, 10.67%; 95% CI, 9.11%-12.26%; P < .001), non-Hispanic Black (AAPC, 9.20%; 95% CI, 7.32%-11.11%; P < .001), and non-Hispanic Asian (AAPC, 7.97%; 95% CI, 4.66%-11.75%; P < .001) individuals, while the projected values for these 4 groups showed similar increasing trends to 2040. There were also significant differences in ASMRs by metropolitan categories overall, with the highest rise in nonmetropolitan areas (AAPC, 13.50%; 95% CI, 10.70%-16.32%; P < .001).Conclusions and Relevance: In this cross-sectional study, MASLD-related mortality increased rapidly between 2006 and 2023 and was projected to rise over the next 20 years, with the largest disparities among those aged 65 years and older, among non-Hispanic White and Hispanic individuals, and among nonmetropolitan populations.Keywords
This publication has 37 references indexed in Scilit:
- Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow‐upHepatology, 2019
- Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United StatesHepatology Communications, 2019
- Nonalcoholic Fatty Liver Disease and Renal Function Impairment: A Cross‐Sectional Population‐Based Study on Its Relationship From 1999 to 2016Hepatology Communications, 2019
- Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016Hepatology International, 2019
- Prevalence of Nonalcoholic Fatty Liver Disease in the Female PopulationHepatology Communications, 2018
- Differences in Rural and Urban Health Information Access and UseThe Journal of Rural Health, 2018
- Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2018
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- Obesity and obesity-related behaviors among rural and urban adults in the USARural and Remote Health, 2015